Prosecution Insights
Last updated: April 19, 2026
Application No. 18/289,214

COMPOUNDS FOR MODULATING PLATELET-TYPE 12-(S)-LIPOXYGENASE AND METHODS OF USE FOR SAME

Non-Final OA §112§DP
Filed
Nov 01, 2023
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of California
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 11m
To Grant
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
869 granted / 1225 resolved
+10.9% vs TC avg
Minimal +0% lift
Without
With
+0.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
1268
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1225 resolved cases

Office Action

§112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Election/Restrictions 2. Applicant’s election without traverse of Group I in the reply filed on FILLIN "Enter mail date of the reply." \* MERGEFORMAT March 6, 2026 is acknowledged. 3. The election of species requirement is withdrawn. The full scope of the elected group was searched and examined. 4. Claim s 13 and 14 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter . Election was made without traverse in the reply filed on March 6, 2026 . Information Disclosure Statement 5. The information disclosure statement s (dated December 19, 2024 and May 13, 2025) were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98 . The statements were considered . Signed copies of form 1449 are enclosed herewith. Status of Claims 6. Claims 1-15 are pending. Claims 1-12 are elected. Claims 1 and 12 are independent. Claim Objections 7. Claims 7 and 11 are objected to because of the following informality: the claims are missing a period. 8. Claim s 7 and 11 are objected to because of the following informality: compounds in the claims are cut off. See lines 1 and 3 on claim 7 and lines 1, 5 and 6 on claim 11. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 9. Claim 8 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claim recites a definition for variable Y4. However, the Markush formula does not contain a variable Y4. It is unclear whether the definition is extraneous and unnecessary, or whether the Markush formula provided in the claim is incorrect. Claim 10 recites the limitation s " A, m, Ra . ” There is insufficient antecedent basis for this limitation in the claim. These variables are not recited in claim 8 which is the claim from which it depends. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg , 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman , 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi , 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum , 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel , 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington , 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer . 10. Claims 1-12 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-3 and 12-15 of copending Application No. 18,992,933 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other for the reasons provided below . This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Regarding claim s 1 and 12 in the present application - c laim 12 of the copending application, directed to compositions comprising compound s of formula IV ( ) anticipates the present claim which is directed to compound s of formula I: ( ) , wherein the variables in IV and I have the same definition. Regarding claims 2-7 in the present application - compound in the copending application ( eg. claim 13 therein) corresponds to the present claims in the following manner: R1=hydroxy; R2=alkoxy; R3=R4=R5=H ; X=S; Y1-Y4=C; A in usubstituted . The compound corresponds to the first compound in claim 7, and the compound in claim 12. Regarding claims 8-12 in the present application - compound in the copending application ( eg. claim 14 therein) corresponds to the present claims in the following manner: Y1-Y3=C; A is unsubstituted. The compound corresponds to the first compound of present claim 11. Allowable Subject Matter 11. Claims 1-12 are novel and nonobvious over the prior art. The point of novelty is the specific structural requirements of Formula I. The closest prior art can be considered to be, for example, US 20200392077 and CID 8603565. US 20200392077 teaches compounds that are lipoxygenase inhibitors and have general structure wherein with specific embodiments of R3 being mono or bicyclic structures. The reference does not teach or suggests the present compounds that have a specific tricyclic ring structure. CID teaches , however, the compound has no utility. The closest references do not anticipate nor make obvious the present invention. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT SUN JAE YOO whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)272-9074 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT Mon-Fri 8-5 . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Nov 01, 2023
Application Filed
Mar 27, 2026
Non-Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595251
AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS
2y 5m to grant Granted Apr 07, 2026
Patent 12594266
TRITERPENOID ANTIFUNGALS FOR THE TREATMENT OR PREVENTION OF PNEUMOCYSTIS SPP. PNEUMONIA
2y 5m to grant Granted Apr 07, 2026
Patent 12583854
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12583855
RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583821
SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.4%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1225 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month